HA
NKTR icon

Herold Advisors’s Nektar Therapeutics NKTR Stock Holding History

Herold Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-680
Closed -$55K – 499
2022
Q1 		$55K Sell
680
-553
-45% -$81.8K 0.02% 365
2021
Q4 		$249K Buy
1,233
+206
+20% +$44.7K 0.1% 177
2021
Q3 		$276K Buy
+1,027
New +$247K 0.11% 164

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Herold Advisors's NKTR Position: Q2 2022 in Review

Herold Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 680 shares — an estimated $55K sold.

Herold Advisors first reported a position in NKTR in Q3 2021 and held it in 3 quarters. The position peaked at $276K in Q3 2021. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Herold Advisors reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Herold Advisors sold 680 Nektar Therapeutics shares in Q2 2022, an estimated $55K.
  • Herold Advisors first reported a position in Nektar Therapeutics in Q3 2021 and held it in 3 quarters.
  • Herold Advisors's Nektar Therapeutics position peaked at $276K in Q3 2021.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Herold Advisors's 13F filing for Q2 2022, filed 15 Jul 2022.